• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).

作者信息

Visani Giuseppe, Breccia Massimo, Montefusco Enrico, Morra Enrica, Santini Valeria, Isidori Alessandro

出版信息

Haematologica. 2011 Apr;96(4):e23-4; author reply e25. doi: 10.3324/haematol.2011.041319.

DOI:10.3324/haematol.2011.041319
PMID:21454871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3069247/
Abstract
摘要

相似文献

1
The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
Haematologica. 2011 Apr;96(4):e23-4; author reply e25. doi: 10.3324/haematol.2011.041319.
2
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.达沙替尼治疗期间的胸腔/心包积液：发生率、处理方法以及与积液发生相关的风险因素。
Expert Opin Drug Saf. 2010 Sep;9(5):713-21. doi: 10.1517/14740331003742935.
3
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.Charlson 共病指数和成人共病评估-27 评分可能预测二线达沙替尼治疗的老年慢性髓系白血病患者的治疗依从性和胸腔积液的发生。
Haematologica. 2011 Oct;96(10):1457-61. doi: 10.3324/haematol.2011.041251. Epub 2011 Jun 17.
4
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.TKI 治疗相关 CML 液体潴留的发生和管理，重点是达沙替尼。
J Hematol Oncol. 2009 Nov 12;2:46. doi: 10.1186/1756-8722-2-46.
5
Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.接受低剂量达沙替尼治疗的慢性髓性白血病患者的胸腔和心包积液
Haematologica. 2011 Mar;96(3):e15; author reply e16-7. doi: 10.3324/haematol.2011.040048.
6
Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?达沙替尼、大颗粒淋巴细胞增多症和胸腔积液：有益还是有害作用？
Crit Rev Oncol Hematol. 2014 Feb;89(2):242-7. doi: 10.1016/j.critrevonc.2013.10.005. Epub 2013 Oct 12.
7
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.与使用二线BCR/ABL酪氨酸激酶抑制剂相关的严重不良事件：在合并症患者中更易发生。
Haematologica. 2011 Oct;96(10):1395-7. doi: 10.3324/haematol.2011.052076.
8
Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.接受达沙替尼治疗的患者发生耶氏肺孢子菌肺炎。
Int J Infect Dis. 2014 Aug;25:165-7. doi: 10.1016/j.ijid.2014.04.030. Epub 2014 Jun 14.
9
Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.一名正在服用酪氨酸激酶抑制剂的慢性粒细胞白血病患者出现严重呼吸困难。
Thorax. 2015 Jul;70(7):701-4. doi: 10.1136/thoraxjnl-2015-206841. Epub 2015 May 2.
10
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.二线达沙替尼治疗后发生 I/II 级胸腔积液的慢性髓系白血病患者比无胸腔积液患者有更好的反应和结局。
Leuk Res. 2014 Jul;38(7):781-7. doi: 10.1016/j.leukres.2014.04.004. Epub 2014 Apr 18.

引用本文的文献

1
Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy.用于心脏病风险分层的血清生物标志物的最新进展以及对接受靶向治疗的血液系统恶性肿瘤患者心脏管理的见解。
Cureus. 2023 Nov 30;15(11):e49696. doi: 10.7759/cureus.49696. eCollection 2023 Nov.
2
Cardiotoxicity of Novel Targeted Hematological Therapies.新型靶向血液学疗法的心脏毒性
Life (Basel). 2020 Dec 11;10(12):344. doi: 10.3390/life10120344.

本文引用的文献

1
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.达沙替尼即使在低剂量时，对于对伊马替尼耐药或不耐受的慢性髓性白血病患者也是一种有效的二线治疗药物。这是一项基于现实生活的意大利多中心回顾性研究对114例患者得出的结果。
Am J Hematol. 2010 Dec;85(12):960-3. doi: 10.1002/ajh.21871.
2
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.慢性髓性白血病患者在接受每天 100 毫克或 50 毫克达沙替尼治疗时发生广泛的胸腔和心包积液。
Haematologica. 2011 Jan;96(1):163-6. doi: 10.3324/haematol.2010.030494. Epub 2010 Oct 7.
3
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.达沙替尼治疗期间的胸腔/心包积液：发生率、处理方法以及与积液发生相关的风险因素。
Expert Opin Drug Saf. 2010 Sep;9(5):713-21. doi: 10.1517/14740331003742935.
4
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.达沙替尼 100 毫克，每日一次，可最大程度减少慢性期慢性髓性白血病患者胸腔积液的发生，并且对发生胸腔积液的患者的疗效没有影响。
Cancer. 2010 Jan 15;116(2):377-86. doi: 10.1002/cncr.24734.
5
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.接受达沙替尼治疗的慢性髓性白血病患者出现的胸腔积液可能具有免疫介导的发病机制。
Br J Haematol. 2008 May;141(5):745-7. doi: 10.1111/j.1365-2141.2008.07108.x. Epub 2008 Mar 7.
6
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.伊马替尼治疗失败后使用达沙替尼治疗的慢性髓性白血病患者的胸腔积液
J Clin Oncol. 2007 Sep 1;25(25):3908-14. doi: 10.1200/JCO.2007.12.0329.